NCT03586661
- Conditions
- Adnexal Diseases, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, +32 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Deleterious BRCA2 Gene Mutation
Explore clinical trials studying Deleterious BRCA2 Gene Mutation. Study availability and eligibility vary by location and protocol.
5 public trials
0 recruiting studies
Deleterious BRCA2 Gene Mutation trial results
NCT03845296
- Conditions
- Adenocarcinoma, Adenocarcinoma of Lung, Bronchial Neoplasms, +23 more
- Locations
-
- University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
Completed
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
NCT02282345
- Conditions
- Breast Adenocarcinoma, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, +2 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations
NCT02760849
- Conditions
- Adnexal Diseases, Breast Diseases, Breast Neoplasms, +33 more
- Locations
-
- University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
- Mayo Clinic Rochester, Minnesota, United States
- Siteman Cancer Center at Washington University St Louis, Missouri, United States
Active, Not Recruiting
Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants
NCT03546972
- Conditions
- Adenocarcinoma, Body Weight, Breast Carcinoma In Situ, +18 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States